Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis

OBJECTIVE: Recent guideline updates have suggested de-escalating DMARDs when patients with rheumatoid arthritis achieve remission or low disease activity. We aim to evaluate whether it is cost-effective to de-escalate the biological form of DMARDs (bDMARDs). METHODS: Using a Markov model, we perform...

Descripción completa

Detalles Bibliográficos
Autores principales: Birkner, Benjamin, Rech, Jürgen, Stargardt, Tom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6939943/
https://www.ncbi.nlm.nih.gov/pubmed/31895926
http://dx.doi.org/10.1371/journal.pone.0226754

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6939943/
https://www.ncbi.nlm.nih.gov/pubmed/31895926
http://dx.doi.org/10.1371/journal.pone.0226754

Ejemplares similares